Powder: -20°C for 3 years | In solvent: -80°C for 1 year
FX-06 (Fibrin-derived peptide Bβ15-42) is a peptide derived from the fibrin Bbeta chain. It interacts with VE-cadherin to inhibit leukocyte transmigration and initiate VE-cadherin-mediated signaling pathways. This compound has applications in researching ischemia/reperfusion injury and Dengue shock syndrome (DSS) [1] [2] [4].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | FX-06 (Fibrin-derived peptide Bβ15-42) is a peptide derived from the fibrin Bbeta chain. It interacts with VE-cadherin to inhibit leukocyte transmigration and initiate VE-cadherin-mediated signaling pathways. This compound has applications in researching ischemia/reperfusion injury and Dengue shock syndrome (DSS) [1] [2] [4]. |
In vitro | FX-06 (50 μM, 3 days) suppresses D2HG synthesis in HEK-293T cells expressing mutant IDH1 R132H [2]. |
In vivo | FX06, administered intravenously at 2.4 mg/kg as a bolus, notably enhances pulmonary and circulatory function in a porcine model of hemorrhagic shock and reperfusion [3]. The same dosage, given intraperitoneally twice daily, increases survival rates and mitigates capillary leakage in Dengue shock syndrome mouse models [4]. When administered at 3.6 mg/kg intravenously, FX06 safeguards against ischemia/reperfusion (I/R)-induced renal damage in mice, promoting epithelial cell proliferation and facilitating tissue repair [5]. |
Synonyms | Fibrin-derived peptide Bβ15-42 |
Molecular Weight | 3039.41 |
Formula | C133H216N44O38 |
CAS No. | 88650-17-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
FX-06 88650-17-3 Fibrin-derived peptide Bβ15-42 inhibitor inhibit